Company Description
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States.
The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen.
It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra.
The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Country | United States |
Founded | 1995 |
IPO Date | Feb 10, 2006 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 102 |
CEO | Ron Cohen |
Contact Details
Address: Two Blue Hill Plaza Pearl River, New York 10965 United States | |
Phone | 914-347-4300 |
Stock Details
Ticker Symbol | ACORQ |
Exchange | OTCMKTS |
Fiscal Year | January - December |
CIK Code | 0001008848 |
CUSIP Number | 00484M106 |
ISIN Number | US00484M6012 |
Employer ID | 13-3831168 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Ron Cohen M.D. | Founder, Chief Executive Officer, President and Director |
Michael A. Gesser M.B.A. | Chief Financial Officer |
Kerry M. Clem | Chief Commercial Officer |
Robert Morales | Interim Principal Accounting Officer, Principal Financial Officer, Vice President of Finance and Controller |
Felicia Vonella | Vice President of Investor Relations |
Neil S. Belloff Esq. | General Counsel and Corporate Secretary |
Tierney Saccavino | Executive Vice President of Corporate Communications |
Denise J. Duca | Executive Vice President of Human Resources |
Andrew Mayer J.D. | Senior Vice President |
Sofia Ali | Senior Vice President of Operations and Strategic Planning |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 29, 2024 | 10-K/A | [Amend] Annual report |
Apr 26, 2024 | 8-K | Current Report |
Apr 25, 2024 | 25-NSE | Filing |
Apr 17, 2024 | 8-K | Current Report |
Apr 4, 2024 | 8-K | Current Report |
Apr 2, 2024 | 8-K | Current Report |
Apr 1, 2024 | 10-K | Annual Report |
Mar 13, 2024 | 8-K | Current Report |
Jan 11, 2024 | 8-K | Current Report |
Dec 1, 2023 | 8-K | Current Report |